Sign In
Buy ACON
$3.49
-0.0100 (-0.286%)
At Close: Jun 03, 2026
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption
06:00am, Thursday, 30'th Apr 2026
Triple-digit annual growth signals accelerating Nociscan adoption and integration into clinical workflows Advancing reimbursement and clinical milestones, with CLARITY trial interim readout anticipate
Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan
06:03am, Tuesday, 28'th Apr 2026
BROOMFIELD, Colo., April 28, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcar
Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan
06:00am, Tuesday, 28'th Apr 2026
Commercial leader with proven track record of driving growth, surgeon adoption, and market expansion with innovative spine and surgical technologies Expansion of commercial team reflects increasing de
PRISM MediaWire – Weekly Press Release Round Up – April 20 to April 24, 2026 – Top Financial & Corporate News Highlights
11:26am, Friday, 24'th Apr 2026
$AERA $BCBC $ACON $SKYX $AUUD $SSII $BIEI $ATCH PRISM MarketViev About PRISM MediaWire PRISM MediaWire is a New York City–based press release distribution company specializing in capital markets com
Aclarion Announces $2.5 Million Stock Repurchase Plan
08:31am, Wednesday, 22'nd Apr 2026
Highlights Disciplined Capital Allocation While Supporting Continued Nociscan® Adoption Broomfield, CO, April 22, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – A
Aclarion Announces $2.5 Million Stock Repurchase Plan
08:30am, Wednesday, 22'nd Apr 2026
BROOMFIELD, Colo., April 22, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomark
Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain
06:48am, Thursday, 16'th Apr 2026
Broomfield, CO, April 16, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercia
Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain
06:47am, Thursday, 16'th Apr 2026
Patent covers use of AI in workflows of future products to accelerate company's ability to scale and enhance already strong gross margins Expands intellectual property portfolio to 64 issued and pendi
Aclarion Receives Pinnacle Award for AI Innovation
08:00am, Tuesday, 14'th Apr 2026
Recognition Follows 2025 HLTH Digital Health Award for Nociscan Award Winning AI Targets a Large and Costly Chronic Low Back Pain Market BROOMFIELD, Colo., April 14, 2026 (GLOBE NEWSWIRE) -- Aclarion,
Aclarion Announces Agreement with Weill Cornell Medicine
08:01am, Wednesday, 08'th Apr 2026
Expands use of Nociscan in groundbreaking trial Broomfield, CO, April 8, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
Aclarion Announces Agreement with Weill Cornell Medicine
08:00am, Wednesday, 08'th Apr 2026
BROOMFIELD, Colo., April 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging
Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video
08:00am, Tuesday, 07'th Apr 2026
Video featuring Mr. John Sutcliffe, Lead Clinician at The London Spine Clinic, highlights real-world physician experience with Nociscan in clinical practice Nearly 100 Nociscans performed at The Londo
Todos Med (OTCMKTS:TOMDF) and Aclarion (NASDAQ:ACON) Head-To-Head Survey
01:15am, Saturday, 28'th Mar 2026
Aclarion (NASDAQ: ACON - Get Free Report) and Todos Med (OTCMKTS:TOMDF - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the stre
Echo Lake Capital Calls for the Resignation of David Neal From the Board of Directors of Aclarion Inc.
08:00am, Tuesday, 24'th Mar 2026
Stock has declined 99% since its IPO Believes Neal has repeatedly failed to fulfill his fiduciary responsibility Since 2021 Neal has received $240,000 Board compensation Accepted 20% pay increase in 2
Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan
09:26am, Thursday, 19'th Mar 2026
BROOMFIELD, Colo., March 19, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc. (Nasdaq: ACON, ACONW) (“Aclarion” or the “Company”) today announ
